News and information on branded drugs sold in retail pharmacies, as well as their suppliers.
Abbott's FreeStyle Libre 2 continuous glucose monitoring system does not require fingersticks.
The indication to treat non-radiographic axial spondyloarthritis is the fourth FDA-approved indication for Novartis’ Cosentyx.
Dr. Reddy's will manufacture remdesivir, Gilead's investigational antiviral therapy used to treat COVID-19.
Chiesi Group’s Ferriprox (deferiprone) comes in twice a day 1,000-mg oral tablets, eliminating the midday dose.
The FDA has given the green light for new indication's for Lilly's Cyramz, and Taltz.
AstraZeneca's Farxiga provides a treatment option for heart failure patients with reduced ejection fraction.
Dr. Reddy's Elyxyb will provide treatment for adults with acute migraine with or without aura.
Novartis' Tabrecta is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer with a mutation that leads to MET exon 14 skipping.
Teva's Ajovy injection offers quarterly or monthly dosing options for migraine patients.
GSK’s Zejula is the only oral monotherapy available as a first-line maintenance treatment for women regardless of BRCA mutational status, addressing a high unmet need in ovarian cancer.
As it moves into its second century in business, Upsher-Smith Labs is focusing on innovating and growing its product offerings while maintaining its high standards.
Vyepti is the first and only intravenous treatment for migraine prevention.
Lundbeck’s Vyepti is the first and only intravenous preventive treatment for migraine.
Neurelis’ Valtoco is the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients age 6 years old and older.